NBIX 2Q26: Still riding the Crenessity launch wave

Research evidence excerpt

NBIX 2Q26: Still riding the Crenessity launch wave

Jeffrey Walch, MD, Ph.D. +1 917 344 8613 jeffrey.walch@bernsteinsg.com 30 July 2026

Certain affiliates of Bernstein act as market maker or liquidity provider in the equities securities of: Neurocrine Biosciences Inc.

OTHER MATTERS

The legal entity(ies) employing the analyst(s) listed in this report, and their location, can be determined by the country code of their

phone number, as follows:

+1 Bernstein Institutional Services LLC; New York, New York, USA

+44 Bernstein Autonomous LLP; London UK

+212 Société Générale Africa Technologies & Services; Casablanca, Morocco

+33 BSG France S.A.; Paris, France

+34 BSG France S.A.; Madrid, Spain

+41 Bernstein Autonomous LLP; Geneva, Switzerland

+49 BSG France S.A.; Frankfurt, Germany

+91 Sanford C. Bernstein (India) Private Limited; Mumbai, India

+852 Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司; Hong Kong, China

+65 Sanford C. Bernstein (Singapore) Private Limited; Singapore

+81 Sanford C. Bernstein Japan KK; Tokyo, Japan

Where this report has been prepared by research analyst(s) employed by a non-US affiliate, such analyst(s), is/are (unless

otherwise expressly noted below) not registered as associated persons of Bernstein Institutional Services LLC or any other SEC-

registered broker-dealer and are not licensed or qualified as research analysts with FINRA. Accordingly, such analyst(s) may not

be subject to FINRA’s restrictions regarding (among other things) communications by research analysts with a subject company,

interactions between research analysts and investment banking personnel, participation by research analysts in solicitation and

marketing activities relating to investment banking transactions, public appearances by research analysts, and trading securities